Effect of a Plant Based Nootropic on Perceptual Decision Making.

NCT ID: NCT06689644

Last Updated: 2024-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-23

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Nootropics are a group of medicinal substances purported to improve important cognitive functions such as learning, focus and memory. Many of these substances have demonstrated beneficial effects on cognitive performance and overall health. However, a thorough understanding of how these substances and their synergistic effects in the form of a supplement may benefit fundamental brain processes is currently lacking. In the current study, we will investigate the effects of a plant-based, nootropic supplement (https://uk.mindlabpro.com/) on perceptual decision-making (i.e. the ability to make rapid decisions based on sensory stimuli) in healthy adult participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will perform a computerised cognitive task assessing their perceptual decision-making pre- and post- 60 days of continuous supplementation with either a plant-based nootropic supplement (Mind Lab pro) or placebo. During testing, electroencephalography (EEG) signals will be captured simultaneously.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Enhancement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

This group will receive the nootropic supplement for 60 days.

Group Type EXPERIMENTAL

Nootropics (ginkgo biloba, nicergoline, piracetam, or others)

Intervention Type DIETARY_SUPPLEMENT

Commercially available product: Mind lab pro

Perceptual decision-making performance

Intervention Type BEHAVIORAL

A computerised cognitive task involving rapid visual categorisation of images

Electroencephalography

Intervention Type DEVICE

Brain signals are recorded from a 64 channel EEG system during the cognitive task

Control group

This group will receive a placebo supplement for 60 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

A cellulose commonly used as a bulking agent in supplement products

Perceptual decision-making performance

Intervention Type BEHAVIORAL

A computerised cognitive task involving rapid visual categorisation of images

Electroencephalography

Intervention Type DEVICE

Brain signals are recorded from a 64 channel EEG system during the cognitive task

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nootropics (ginkgo biloba, nicergoline, piracetam, or others)

Commercially available product: Mind lab pro

Intervention Type DIETARY_SUPPLEMENT

Placebo

A cellulose commonly used as a bulking agent in supplement products

Intervention Type DIETARY_SUPPLEMENT

Perceptual decision-making performance

A computerised cognitive task involving rapid visual categorisation of images

Intervention Type BEHAVIORAL

Electroencephalography

Brain signals are recorded from a 64 channel EEG system during the cognitive task

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:

* Eligibility screening of participants was guided by the following inclusion criteria: (i) be between 20-59 years old, (ii) be right-handed and (iii) be able to cease taking other dietary supplements for two months.

Exclusion Criteria:

* Exclusion criteria included: (i) currently consuming a nootropic supplement, (ii) any known musculoskeletal, or neurological medical conditions or cognitive impairments (iii) have a known diagnosis of epilepsy/history of seizures and (iv) have a known hearing or visual condition that affects daily life function.
Minimum Eligible Age

20 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Leeds

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Andrea Utley

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ioannis Delis

Role: PRINCIPAL_INVESTIGATOR

University of Leeds

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Biological sciences

Leeds, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

O'Reilly D, Bolam J, Delis I, Utley A. Effect of a Plant-Based Nootropic Supplement on Perceptual Decision-Making and Brain Network Interdependencies: A Randomised, Double-Blinded, and Placebo-Controlled Study. Brain Sci. 2025 Feb 21;15(3):226. doi: 10.3390/brainsci15030226.

Reference Type DERIVED
PMID: 40149748 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://osf.io/25afe

Pre-registration of the study

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AUtley

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.